Oct 6, 2025 · Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.

Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications …

At Harrow, our values aren’t just guiding words—they shape how we grow, innovate, and work together. Humility, ownership, preparedness, and entrepreneurship create the foundation for a …

Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications …

The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.

Harrow INC SEC filing: Form 8-K iXBRL on 09/09/2025 (0001493152-25-012840).

Harrow remains focused on expanding patient access and utilization for IHEEZO and TRIESENCE across Medicare and commercial patient populations. This commitment is …

Harrow was established with the core principle of delivering accessible eyecare solutions to both eyecare providers and patients. We are dedicated to helping eligible patients access the …

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical …

SAN DIEGO , May 5, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary …